Cyclooxygenase system contributes to the maintenance of post convulsive period of epileptic phenomena in the genetically epileptic El mice.
Recent studies have shown that cytokines and cyclooxygenase (COX)-2 are up-regulated in the brain of human epilepsy patients and animal models of epilepsy. We investigated the effect of inflammatory responses induced by intramuscular injection of turpentine on the epileptic phenomenon in genetically epileptic El mice. As parameters of epileptic seizure, seizure threshold (number of toss-ups to induce convulsion), duration of actual convulsion and duration of post actual convulsive period (period from the offset of convulsion to full recovery) were evaluated. The post actual convulsive period was prolonged without any change of seizure threshold or duration of actual convulsion 24 h after turpentine injection. Although pretreatment with indomethacin for one week did not change the seizure parameters, indomethacin suppressed the prolongation of the post actual convulsive period induced by turpentine. The mRNA expression of IL-1beta, IL-6 and COX-2 in the cerebral cortex was detected by RT-PCR. There was no difference in the mRNA expression in the cerebral cortex before and 24 h after seizure. The mRNA levels of IL-1beta, IL-6 and COX-2 in the cerebral cortex were up-regulated 24 h after turpentine injection. On the other hand, the up-regulated mRNA levels of IL-1beta, IL-6 and COX-2 in the cerebral cortex after turpentine treatment were not suppressed by indomethacin. These results suggest that prostaglandins induced with COX-2 in the cerebral cortex seem to play an important role in the maintenance of the post convulsive period, but not in induction and maintenance of the actual convulsive state.
Okada
Kazumasa
K
Department of Neurology, School of Medicine, University of Occupational and Environmental Health, Yahatanishiku, Kitakyushu 807-8555, Japan.
Yamashita
Uki
U
Tsuji
Sadatoshi
S
D000818:Animals; D002540:Cerebral Cortex / Q000737:chemistry; D051546:Cyclooxygenase 2 / Q000032:analysis / Q000502:physiology*; D004195:Disease Models, Animal; D004827:Epilepsy / Q000151:congenital / Q000201:enzymology / Q000503:physiopathology*; D007213:Indomethacin; D007273:Injections, Intramuscular; D007375:Interleukin-1 / Q000502:physiology; D015850:Interleukin-6 / Q000032:analysis / Q000502:physiology; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D011451:Prostaglandin-Endoperoxide Synthases / Q000502:physiology*; D012333:RNA, Messenger / Q000032:analysis; D012640:Seizures / Q000503:physiopathology; D014425:Turpentine / Q000008:administration & dosage
D007375:Interleukin-1; D015850:Interleukin-6; D012333:RNA, Messenger; D051546:Cyclooxygenase 2; D011451:Prostaglandin-Endoperoxide Synthases; D014425:Turpentine; D007213:Indomethacin